# Topotecan, Paclitaxel, and Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

> **NCT00004055** · PHASE2 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 38 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** paclitaxel
- **DRUG:** topotecan hydrochloride

## Key facts

- **NCT ID:** NCT00004055
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-11
- **Primary completion:** 2004-07
- **Final completion:** 2004-07
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2016-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004055, "Topotecan, Paclitaxel, and Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00004055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*